Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study | Paparrigopoulos et al. BMC Psychiatry 2011 11 41 http www.biomedcentral.com 1471-244X 11 41 BMC Psychiatry RESEARCH ARTICLE Open Access Treatment of alcohol dependence with low-dose topiramate an open-label controlled study 1 1 1 2 1 Thomas Paparrigopoulos Elias Tzavellas Dimitris Karaiskos Georgia Kourlaba loannis Liappas 1 Abstract Background GABAergic anticonvulsants have been recommended for the treatment of alcohol dependence and the prevention of relapse. Several studies have demonstrated topiramate s efficacy in improving drinking behaviour and maintaining abstinence. The objective of the present open-label controlled study was to assess efficacy and tolerability of low-dose topiramate as adjunctive treatment in alcohol dependence during the immediate postdetoxification period and during a 16-week follow-up period after alcohol withdrawal. Methods Following a 7-10 day inpatient alcohol detoxification protocol 90 patients were assigned to receive either topiramate up to 75 mg per day in addition to psychotherapeutic treatment n 30 or psychotherapy alone n 60 . Symptoms of depression and anxiety as well as craving were monitored for 4-6 weeks immediately following detoxification on an inpatient basis. Thereafter both groups were followed as outpatients at a weekly basis for another 4 months in order to monitor their course and abstinence from alcohol. Results A marked improvement in depressive p 0.01 anxiety p 0.01 and obsessive-compulsive drinking symptoms p 0.01 was observed over the consecutive assessments in both study groups. However individuals on topiramate fared better than controls p 0.01 during inpatient treatment. Moreover during the 4-month follow up period relapse rate was lower among patients who received topiramate 66.7 compared to those who received no adjunctive treatment 85.5 p 0.043 . Time to relapse in the topiramate augmentation group was significantly longer compared to the control group log rank test p 0.008 . Thus median duration of .